Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.
| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q4 2025 | Exited | −39K | – | −100.0% | 0 | Feb 17, 2026 |
| Q3 2025 | Added | +5K | – | +14.1% | 39K | Nov 14, 2025 |
| Q2 2025 | New | +34K | – | – | 34K | Aug 14, 2025 |
| Q4 2024 | New | +64K | – | – | 64K | Feb 14, 2025 |
| Q2 2024 | Reduced | −4K | – | −6.1% | 67K | Aug 14, 2024 |
| Q1 2024 | Added | +6K | – | +8.6% | 72K | May 15, 2024 |
| Q4 2023 | Added | +39K | – | +145.8% | 66K | Feb 14, 2024 |
| Q3 2023 | Reduced | −12K | – | −30.6% | 27K | Nov 14, 2023 |
| Q2 2023 | Reduced | −38K | – | −49.5% | 39K | Aug 14, 2023 |
| Q1 2023 | Reduced | −4K | – | −4.8% | 77K | May 15, 2023 |
| Q4 2022 | Reduced | −45K | – | −36.1% | 81K | Feb 14, 2023 |
| Q3 2022 | Added | +51K | – | +68.3% | 126K | Nov 14, 2022 |
| Q2 2022 | Added | +532 | – | +0.7% | 75K | Aug 15, 2022 |
| Q1 2022 | Added | +46K | – | +160.1% | 74K | May 16, 2022 |
| Q4 2021 | Added | +18K | – | +172.2% | 29K | Feb 14, 2022 |
| Q3 2021 | New | +10K | – | – | 10K | Nov 15, 2021 |
| Q1 2021 | First covered | – | – | – | 2K | May 17, 2021 |
Not currently. Joel Greenblatt fully exited MRNA in Q4 2025, and the complete history is above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Joel Greenblatt held MRNA since at least Q1 2021, when this filing coverage begins; the opening snapshot is not a disclosed purchase. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Yes. Joel Greenblatt reduced and then fully exited MRNA by Q4 2025; the reductions are in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
None as of the latest filing: Joel Greenblatt has exited MRNA. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Joel Greenblatt began building the MRNA position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
